Comparative Pharmacology
Head-to-head clinical analysis: TRI LEGEST 21 versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LEGEST 21 versus VIORELE.
TRI-LEGEST 21 vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH), inhibits ovulation, alters cervical mucus and endometrium.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
One tablet orally once daily for 21 days, followed by 7 tablet-free days. Each tablet contains norgestimate 0.18 mg/ethinyl estradiol 0.025 mg (days 1-7), norgestimate 0.215 mg/ethinyl estradiol 0.025 mg (days 8-14), norgestimate 0.25 mg/ethinyl estradiol 0.025 mg (days 15-21).
50 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norgestimate active metabolite (norelgestromin): 22-36 hours (mean ~28 hours). Steady-state achieved within 5-10 days.
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Renal: approximately 50-60% as metabolites; fecal: approximately 40-50% (ethinyl estradiol and norgestimate metabolites excreted in bile and feces); less than 1% unchanged in urine.
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive